145 related articles for article (PubMed ID: 35914785)
1. Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis.
Nozawa T; Bell-Peter A; Marcuz JA; Whitney K; Vinik O; Shupak R; Dover S; Feldman BM
J Rheumatol; 2022 Nov; 49(11):1250-1255. PubMed ID: 35914785
[TBL] [Abstract][Full Text] [Related]
2. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
Fisler RE; Liang MG; Fuhlbrigge RC; Yalcindag A; Sundel RP
J Am Acad Dermatol; 2002 Oct; 47(4):505-11. PubMed ID: 12271292
[TBL] [Abstract][Full Text] [Related]
3. The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
Cancarini P; Nozawa T; Whitney K; Bell-Peter A; Marcuz JA; Taddio A; Guo J; Dover S; Feldman BM
Semin Arthritis Rheum; 2022 Dec; 57():152104. PubMed ID: 36183479
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
Marhaug G; Shah V; Shroff R; Varsani H; Wedderburn LR; Pilkington CA; Brogan PA
Rheumatology (Oxford); 2008 Jul; 47(7):1031-7. PubMed ID: 18448482
[TBL] [Abstract][Full Text] [Related]
5. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study.
Clemente G; Piotto DG; Barbosa C; Peracchi OA; Len CA; Hilário MO; Terreri MT
Rev Bras Reumatol; 2012 Aug; 52(4):549-53. PubMed ID: 22885422
[TBL] [Abstract][Full Text] [Related]
6. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
7. What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis?
Wargula JC; Lovell DJ; Passo MH; Bove KE; Santangelo JD; Levinson JE
Clin Exp Rheumatol; 2006; 24(3):333-43. PubMed ID: 16870106
[TBL] [Abstract][Full Text] [Related]
8. Juvenile dermatomyositis in Thai children: Retrospective review of 30 cases from a tertiary care center.
Nitiyarom R; Charuvanij S; Likasitwattanakul S; Thanoophunchai C; Wisuthsarewong W
Indian J Dermatol Venereol Leprol; 2022; 88(2):162-170. PubMed ID: 34491668
[TBL] [Abstract][Full Text] [Related]
9. Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review.
Gonçalves Júnior J; Shinjo SK
Curr Rheumatol Rep; 2024 Feb; 26(2):53-68. PubMed ID: 38060107
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and disease course of patients with juvenile dermatomyositis.
Gowdie PJ; Allen RC; Kornberg AJ; Akikusa JD
Int J Rheum Dis; 2013 Oct; 16(5):561-7. PubMed ID: 24164844
[TBL] [Abstract][Full Text] [Related]
11. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
Saini I; Kalaivani M; Kabra SK
Rheumatol Int; 2016 Jul; 36(7):961-5. PubMed ID: 27007612
[TBL] [Abstract][Full Text] [Related]
12. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
Hoeltzel MF; Oberle EJ; Robinson AB; Agarwal A; Rider LG
Curr Rheumatol Rep; 2014 Dec; 16(12):467. PubMed ID: 25366934
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib].
Zhou QF; Luo Y; He TY; Ling JY; Xu YB; Yang J; Xia Y
Zhonghua Er Ke Za Zhi; 2023 Jun; 61(6):538-542. PubMed ID: 37312466
[No Abstract] [Full Text] [Related]
14. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis.
Schmeling H; Stephens S; Goia C; Manlhiot C; Schneider R; Luthra S; Stringer E; Feldman BM
Rheumatology (Oxford); 2011 May; 50(5):885-93. PubMed ID: 21156669
[TBL] [Abstract][Full Text] [Related]
15. Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis.
Wang A; Morgan GA; Paller AS; Pachman LM
J Am Acad Dermatol; 2021 Jun; 84(6):1610-1618. PubMed ID: 33359787
[TBL] [Abstract][Full Text] [Related]
16. Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of disease activity.
Pachman LM; Morgan G; Klein-Gitelman MS; Ahsan N; Khojah A
Pediatr Rheumatol Online J; 2023 Oct; 21(1):118. PubMed ID: 37828536
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis.
Tayfur AC; Topaloglu R; Gulhan B; Bilginer Y
Mod Rheumatol; 2015 Jul; 25(4):615-20. PubMed ID: 25800510
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study.
Okong'o LO; Esser M; Wilmshurst J; Scott C
Pediatr Rheumatol Online J; 2016 Nov; 14(1):60. PubMed ID: 27835954
[TBL] [Abstract][Full Text] [Related]
19. Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
Shiari R; Khalili M; Zeinali V; Shashaani N; Samami M; Moghaddamemami FH
Pediatr Rheumatol Online J; 2024 Jan; 22(1):2. PubMed ID: 38166943
[TBL] [Abstract][Full Text] [Related]
20. Juvenile Dermatomyositis in Afro-Caribbean children: a cohort study in the French West Indies.
Felix A; Delion F; Louis-Sidney F; Osei L; Armougon A; Bellance R; Dramé M; Deligny C; Suzon B; Hatchuel Y
Pediatr Rheumatol Online J; 2023 Oct; 21(1):113. PubMed ID: 37805487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
